Compass Therapeutics (CMPX) Other financing activities (2020 - 2026)

Compass Therapeutics has disclosed Other financing activities across 6 years of filings, most recently posting -$489000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at -$489000.0, up 40.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 million (up 6691.18% YoY), and the FY2025 annual result was $8.6 million, up 1490.79% from the prior year.
• Other financing activities came in at -$489000.0 for Q1 2026 at Compass Therapeutics, down from $8.6 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $8.6 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
• The 4-year median for Other financing activities is -$2000.0 (2024), against an average of $937555.6.
• Peak annual rise in Other financing activities reached 431800.0% in 2025, while the deepest fall reached 499.26% in 2025.
• Compass Therapeutics' Other financing activities stood at -$254000.0 in 2023, then soared by 99.21% to -$2000.0 in 2024, then jumped by 432000.0% to $8.6 million in 2025, then slumped by 105.66% to -$489000.0 in 2026.
• The last three Other financing activities figures came in at -$489000.0 (Q1 2026), $8.6 million (Q3 2025), and $815000.0 (Q2 2025), per Business Quant data.